NASDAQ:SRDX Surmodics (SRDX) Stock Price, News & Analysis $36.00 +3.95 (+12.32%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$38.12 +2.13 (+5.90%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Surmodics Stock (NASDAQ:SRDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Surmodics alerts:Sign Up Key Stats Today's Range$31.84▼$36.1450-Day Range$28.70▼$36.0052-Week Range$26.00▼$41.77Volume519,340 shsAverage Volume101,743 shsMarket Capitalization$514.76 millionP/E RatioN/ADividend YieldN/APrice Target$43.00Consensus RatingModerate Buy Company Overview Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. Read More Surmodics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreSRDX MarketRank™: Surmodics scored higher than 81% of companies evaluated by MarketBeat, and ranked 111th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingSurmodics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSurmodics has only been the subject of 1 research reports in the past 90 days.Read more about Surmodics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth300.00% Earnings GrowthEarnings for Surmodics are expected to grow by 300.00% in the coming year, from $0.20 to $0.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surmodics is -25.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surmodics is -25.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSurmodics has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Surmodics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.49% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Surmodics has recently decreased by 14.76%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSurmodics does not currently pay a dividend.Dividend GrowthSurmodics does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.52 Percentage of Shares Shorted2.49% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Surmodics has recently decreased by 14.76%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment1.10 News SentimentSurmodics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Surmodics this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Surmodics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.90% of the stock of Surmodics is held by insiders.Percentage Held by Institutions96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Surmodics' insider trading history. Receive SRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRDX Stock News HeadlinesSurmodics jumps amid pre-trial hearing in FTC's suit to block sale to GTCRJuly 25 at 7:07 PM | msn.comSurmodics, Inc. (SRDX) stock price, news, quote & history - Yahoo FinanceJuly 3, 2025 | au.finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history. | Paradigm Press (Ad)QuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound?June 6, 2025 | msn.comAre Options Traders Betting on a Big Move in Surmodics Stock?May 2, 2025 | msn.comSurmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial GuidanceApril 30, 2025 | businesswire.comA Look at Surmodics's Upcoming Earnings ReportApril 30, 2025 | benzinga.comSurmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30April 28, 2025 | businesswire.comSee More Headlines SRDX Stock Analysis - Frequently Asked Questions How have SRDX shares performed this year? Surmodics' stock was trading at $39.60 at the start of the year. Since then, SRDX stock has decreased by 9.1% and is now trading at $36.00. How were Surmodics' earnings last quarter? Surmodics, Inc. (NASDAQ:SRDX) issued its quarterly earnings results on Wednesday, April, 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.07. The firm earned $28.09 million during the quarter, compared to the consensus estimate of $32.23 million. Surmodics had a negative net margin of 16.34% and a negative trailing twelve-month return on equity of 7.10%. Who are Surmodics' major shareholders? Surmodics' top institutional investors include Inspire Investing LLC (0.09%). Insiders that own company stock include Timothy J Arens, David Dantzker, Ronald B Sr Kalich Sr and Jose H Bedoya. View institutional ownership trends. How do I buy shares of Surmodics? Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Surmodics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Surmodics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW). Company Calendar Last Earnings4/30/2025Today7/25/2025Next Earnings (Estimated)7/30/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:SRDX CIK924717 Webwww.surmodics.com Phone(952) 500-7000Fax952-500-7001Employees450Year Founded1979Price Target and Rating Average Price Target for Surmodics$43.00 High Price Target$43.00 Low Price Target$43.00 Potential Upside/Downside+19.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.39) Trailing P/E RatioN/A Forward P/E Ratio180.00 P/E GrowthN/ANet Income-$11.54 million Net Margins-16.34% Pretax Margin-11.99% Return on Equity-7.10% Return on Assets-4.77% Debt Debt-to-Equity Ratio0.27 Current Ratio5.14 Quick Ratio3.99 Sales & Book Value Annual Sales$126.08 million Price / Sales4.08 Cash Flow$0.35 per share Price / Cash Flow103.59 Book Value$8.33 per share Price / Book4.32Miscellaneous Outstanding Shares14,300,000Free Float13,026,000Market Cap$514.80 million OptionableOptionable Beta1.31 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SRDX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surmodics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.